CFM
XFOR icon

Catalyst Funds Management’s X4 Pharmaceuticals XFOR Stock Holding History

Catalyst Funds Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$196K Buy
+47,383
New +$177K 0.03% 461

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Catalyst Funds Management's XFOR Position: Q1 2026 in Review

Catalyst Funds Management opened a new position in X4 Pharmaceuticals (XFOR) in Q1 2026: 47,383 shares worth $196K. The stake represents 0.03% of the portfolio and ranks #461 among its holdings.

84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • Catalyst Funds Management held 47,383 shares of X4 Pharmaceuticals worth $196K as of Q1 2026.
  • X4 Pharmaceuticals was a new Catalyst Funds Management position in Q1 2026.
  • X4 Pharmaceuticals made up 0.03% of Catalyst Funds Management's portfolio in Q1 2026, its #461 holding.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Catalyst Funds Management's 13F filing for Q1 2026, filed 11 May 2026.